Similar articles for PMID: 34410991

Year	Number of Results
2016	11
2017	16
2018	31
2019	34
2020	30
2021	32
2022	26
2023	7
2024	0

1

Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.

DE Carlo E, Schiappacassi M, Pelizzari G, Baresic T, Del Conte A, Stanzione B, DA Ros V, Doliana R, Baldassarre G, Bearz A. DE Carlo E, et al. In Vivo. 2021 Sep-Oct;35(5):2941-2945. doi: 10.21873/invivo.12586. In Vivo. 2021. PMID: 34410991 Free PMC article.

2

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M. Hochmair MJ, et al. Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z. Target Oncol. 2019. PMID: 30539501 Free PMC article. Clinical Trial.

3

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M. Minari R, et al. Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13. Lung Cancer. 2018. PMID: 29290257

4

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM. Ou SI, et al. Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12. Lung Cancer. 2017. PMID: 28625641 Free article.

5

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.

Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrão MV, Reis LFL, Katz A, Camargo AA. Knebel FH, et al. Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10. Lung Cancer. 2017. PMID: 28625643

6

Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.

Liu Y, Li Y, Ou Q, Wu X, Wang X, Shao YW, Ying J. Liu Y, et al. Lung Cancer. 2018 Apr;118:1-5. doi: 10.1016/j.lungcan.2018.01.015. Epub 2018 Jan 31. Lung Cancer. 2018. PMID: 29571986

7

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer.

Lee J, Shim JH, Park WY, Kim HK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Lee J, et al. Cancer Res Treat. 2019 Jan;51(1):408-412. doi: 10.4143/crt.2018.138. Epub 2018 May 23. Cancer Res Treat. 2019. PMID: 29807405 Free PMC article.

8

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.

Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB. Rangachari D, et al. J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1. J Thorac Oncol. 2019. PMID: 31377341 Free PMC article.

9

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.

Li C, Jia R, Liu H, Zhang B, Wang C. Li C, et al. Diagn Pathol. 2018 Aug 13;13(1):49. doi: 10.1186/s13000-018-0728-6. Diagn Pathol. 2018. PMID: 30103780 Free PMC article.

10

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K. Takahama T, et al. Cancer. 2020 Jan 1;126(9):1940-1948. doi: 10.1002/cncr.32749. Epub 2020 Feb 5. Cancer. 2020. PMID: 32022929 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

155 results

Results by year